サンプル依頼リスト カート
  • English
  • Korean
表紙：偽性腸閉塞症治療の世界市場レポート 2024年
市場調査レポート
商品コード
1415742

偽性腸閉塞症治療の世界市場レポート 2024年

Intestinal Pseudo-Obstruction Treatment Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
偽性腸閉塞症治療の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

偽性腸閉塞症治療市場規模は近年力強く成長しています。2023年の220億6,000万米ドルから2024年には234億6,000万米ドルに、CAGR6.3％で拡大します。実績期間の成長は、認知度と診断の向上、医療用画像の進歩、消化管運動性検査の進歩、世界ヘルスケアへのアクセスに起因します。

偽性腸閉塞症治療市場規模は、今後数年間で力強い成長が見込まれます。2028年にはCAGR5.5％で290億4,000万米ドルに成長します。予測期間の成長は、研究開発と医薬品開発、遠隔医療と遠隔モニタリング、患者教育とサポート、償還政策に起因します。予測期間の主な動向には、高度な消化管運動検査、免疫調節療法、栄養介入、データ分析、aiなどがあります。

パーキンソン病の有病率の増加は、当面の偽性腸閉塞症（IPO）治療市場拡大の大きな要因になると予測されます。パーキンソン病は、主に脳の黒質領域にあるドーパミン産生ニューロンに影響を及ぼす神経変性疾患です。パーキンソン病患者におけるIPOの罹患率の増加は、腸神経系への影響に起因しており、消化管運動障害を引き起こし、巨大結腸症や急性結腸性仮性閉塞のような状態を引き起こす可能性があります。例えば、米国を拠点とする非営利団体Parkinson's Foundationによると、2022年12月現在、パーキンソン病の診断件数は顕著に増加しており、年間約9万人の米国人がパーキンソン病と診断されています。さらに、2030年までに世界のパーキンソン病患者数は120万人に達すると予測されています。その結果、パーキンソン病患者の増加は、偽性腸閉塞症治療市場成長の原動力となっています。

がん罹患率の増加は、近い将来、腸閉塞（IPO）治療市場拡大の重要な触媒になると予想されます。がんは、体内の特定の細胞の制御不能な増殖と拡散を特徴とします。座りがちな生活、食生活の乱れ、タバコの使用などの生活習慣は、がん発症リスクの上昇に寄与します。がんと併発するIPOの場合、治療の第一の焦点は、仮性閉塞に関連する胃腸症状の改善または解消につながる、根本的ながんへの対処です。例えば、2021年5月、米国を拠点とする医療情報資源である国立医学図書館によると、がんの世界的負担は2020年から47％急増し、2040年までに推定2,840万症例になると予測されています。その結果、がんの罹患率の増加は偽性腸閉塞症（IPO）治療市場の成長を促進する極めて重要な役割を果たします。

2023年の偽性腸閉塞症治療市場では北米が最大地域でした。偽性腸閉塞症（IPO）治療レポートがカバーしている地域は、アジア太平洋、西欧、中東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界の偽性腸閉塞症治療市場、薬剤クラス別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 抗生物質
  • 抗うつ薬
  • 下痢止め
  • 世界の偽性腸閉塞症治療市場、治療別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 薬剤
  • 手術
  • 食習慣
  • 減圧
  • その他
  • 世界の偽性腸閉塞症治療市場、投与経路別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 経口
  • 静脈内
  • その他
  • 世界の偽性腸閉塞症治療市場、診断別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 身体検査
  • 生検
  • 血液検査
  • 胃内容排出検査
  • 画像検査
  • その他
  • 世界の偽性腸閉塞症治療市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 診療所
  • 病院
  • その他

第7章 地域および国の分析

  • 世界の偽性腸閉塞症治療市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界の偽性腸閉塞症治療市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 偽性腸閉塞症治療市場の競合情勢
  • 偽性腸閉塞症治療市場企業プロファイル
    • F. Hoffmann-La Roche AG
    • Merck Sharp &Dohme Corp
    • Bayer AG
    • Sanofi SA
    • AstraZeneca plc

第31章 その他の主要および革新的な企業

  • GSK plc
  • Takeda Pharmaceutical Company Limited
  • Amgen PLC
  • Boehringer Ingelheim International GmbH
  • Teva Pharmaceutical Industries Ltd.
  • Astellas Pharma Inc.
  • Mylan N.V.
  • Biogen Inc.
  • Penn Medicine
  • Sun Pharmaceutical Industries Ltd.
  • Aurobindo Pharma Ltd
  • Cipla Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Allergan plc
  • Torrent Pharmaceuticals Limited

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r12341

“Intestinal Pseudo-Obstruction Treatment Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on intestinal pseudo-obstruction treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for intestinal pseudo-obstruction treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The intestinal pseudo-obstruction treatment market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Drug Class: Antibiotics; Antidepressants; Antidiarrheals
  • 2) By Treatment: Medication; Surgery; Diet; Decompression; Other Treatments
  • 3) By Route Of Administration: Oral; Intravenous; Other Route Of Administrations
  • 4) By Diagnosis: Physical Examination; Biopsy; Blood Test; Gastric Emptying Tests; Imaging Tests; Other Diagnosis
  • 5) By End User: Clinic; Hospitals; Other End Users
  • Companies Mentioned: F. Hoffmann-La Roche AG; Merck Sharp & Dohme Corp; Bayer AG; Sanofi S.A.; AstraZeneca plc
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Intestinal pseudo-obstruction (IPO) treatment addresses a rare gastrointestinal motility disorder exhibiting symptoms akin to a mechanical bowel obstruction, even in the absence of a physical blockage. The goals of treating intestinal pseudo-obstruction involve symptom relief, enhancement of intestinal motility, complication management, and overall improvement in quality of life.

The primary drug classes encompassed in IPO treatment comprise antibiotics, antidepressants, and antidiarrheals. Antibiotics represent a potent category of medications employed for combating bacterial infections in both human and animal patients. Diverse treatment modalities, such as medication, surgery, dietary adjustments, decompression, and others, are administered via various routes, including oral, intravenous, among others. Multiple diagnostic approaches, including physical examinations, biopsies, blood tests, gastric emptying tests, imaging studies, among others, are utilized by a range of end users, including clinics, hospitals, and other healthcare facilities.

The intestinal pseudo-obstruction market research report is one of a series of new reports from The Business Research Company that provides intestinal pseudo-obstruction market statistics, including intestinal pseudo-obstruction industry global market size, regional shares, competitors with a intestinal pseudo-obstruction market share, detailed intestinal pseudo-obstruction market segments, market trends and opportunities and any further data you may need to thrive in the intestinal pseudo-obstruction industry. This intestinal pseudo-obstruction market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The intestinal pseudo-obstruction treatment market size has grown strongly in recent years. It will grow from $22.06 billion in 2023 to $23.46 billion in 2024 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to increased recognition and diagnosis, advancements in medical imaging, advancements in gastrointestinal motility testing, global healthcare access.

The intestinal pseudo-obstruction treatment market size is expected to see strong growth in the next few years. It will grow to $29.04 billion in 2028 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to research and drug development, telemedicine and remote monitoring, patient education and support, reimbursement policies. Major trends in the forecast period include advanced gastrointestinal motility testing, immunomodulatory therapies, nutritional interventions, data analytics and ai.

The increasing prevalence of Parkinson's disease is anticipated to be a significant driver for the expansion of the intestinal pseudo-obstruction (IPO) treatment market in the foreseeable future. Parkinson's disease is a neurodegenerative condition primarily affecting dopamine-producing neurons in the substantia nigra region of the brain. The heightened incidence of IPO in individuals with Parkinson's disease is attributed to its impact on the enteric nervous system, leading to gastrointestinal dysmotility, potentially resulting in conditions like megacolon or acute colonic pseudo-obstruction. For instance, in December 2022, according to the Parkinson's Foundation, a U.S.-based non-profit organization, there has been a notable increase in Parkinson's disease diagnoses, with approximately 90,000 Americans being identified annually, representing a substantial 50% surge from previous estimates. Moreover, it is projected that by 2030, the global population with Parkinson's disease will reach 1.2 million. Consequently, the escalating cases of Parkinson's disease serve as a driving force for the growth of the intestinal pseudo-obstruction treatment market.

The escalating incidence of cancer is anticipated to be a significant catalyst for the expansion of the intestinal pseudo-obstruction (IPO) treatment market in the foreseeable future. Cancer is characterized by the uncontrolled growth and spread of certain cells within the body. Lifestyle factors such as sedentary behavior, poor dietary habits, and tobacco use contribute to an elevated risk of developing cancer. In cases of IPO occurring alongside cancer, the primary focus of treatment involves addressing the underlying cancer, which can lead to an improvement or resolution of the gastrointestinal symptoms associated with pseudo-obstruction. For instance, in May 2021,according to the National Library of Medicine, a US-based medical resource, the global burden of cancer is projected to surge by 47% from 2020, resulting in an estimated 28.4 million cases by 2040. Consequently, the increasing incidence of cancer plays a pivotal role in driving the growth of the intestinal pseudo-obstruction (IPO) treatment market.

The low incidence rate of intestinal pseudo-obstruction (IPO) is projected to act as a constraint on the growth of the IPO treatment market in the foreseeable future. This relatively low occurrence of IPO can hinder market expansion. As of July 2023, according to the National Library of Medicine, a US-based biomedical library, the annual incidence of acute intestinal pseudo-obstruction is estimated to be approximately 100 cases per 100,000 inpatient admissions. Consequently, the low incidence rate serves as a limiting factor for the growth of the intestinal pseudo-obstruction (IPO) treatment market.

Leading players in the intestinal pseudo-obstruction treatment market are increasingly embracing plant-based remedies to bolster their market presence. Plant-derived supplements offer a promising avenue for mitigating the risk of bowel obstruction through their ability to facilitate regular bowel movements and mitigate inflammation. A notable example is Enzymedica Inc., a US-based pharmaceutical company, which introduced Gut Motility in August 2021. This groundbreaking plant-based supplement is designed to enhance gastrointestinal motility and gastric emptying. Its formulation combines artichoke leaf extract, ginger root CO2 extract, and apple cider vinegar, marking a significant milestone in nutraceutical innovation. The cornerstone of Gut Motility is ProDigest, a triple-standardized blend of artichoke leaf extract and ginger root CO2 extract, supported by clinical evidence demonstrating its efficacy in promoting healthy digestive transit. Furthermore, the inclusion of apple cider vinegar, sourced from US-grown apples, helps maintain a balanced pH in the digestive tract, optimizing metabolic processes.

In May 2023, Ironwood Pharmaceuticals, a pharmaceutical company headquartered in the United States, completed the acquisition of VectivBio Holding AG for an undisclosed sum. This strategic move is poised to bolster Ironwood's innovation capabilities and expand its portfolio, ultimately reshaping the benchmark for care in the field of gastrointestinal (GI) medicine. The acquisition will also propel advancements in the treatment of GI disorders, with VectivBio Holding AG, a clinical-stage biotechnology company based in Switzerland, specializing in the treatment of severe and rare gastrointestinal conditions, including Intestinal Pseudo-Obstruction (IPO).

Major players in the intestinal pseudo-obstruction treatment market are F. Hoffmann-La Roche AG, Merck Sharp & Dohme Corp, Bayer AG, Sanofi S.A., AstraZeneca PLC, GSK PLC, Takeda Pharmaceutical Company Limited, Amgen PLC, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Mylan N.V., Biogen Inc., Penn Medicine, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Cipla Inc., Dr. Reddy's Laboratories Ltd., Allergan PLC, Torrent Pharmaceuticals Limited, Basilea Pharmaceutica Ltd., Paratek Pharmaceuticals Inc., Melinta Therapeutics LLC, Tetraphase Pharmaceuticals Inc., Callisto Pharmaceuticals Inc.

North America was the largest region in the intestinal pseudo-obstruction treatment market in 2023. The regions covered in intestinal pseudo-obstruction (IPO) treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the intestinal pseudo-obstruction (IPO) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The intestinal pseudo-obstruction (IPO) treatment market consists of revenues earned by providing entities by providing surgical interventions, decompression and nutrition support. The market value includes the value of related goods sold by the service provider or included within the service offering. The intestinal pseudo-obstruction (IPO) treatment market also includes sales of narcotics, laxatives and pro-kinetics. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Intestinal Pseudo-Obstruction Treatment Market Characteristics

3. Intestinal Pseudo-Obstruction Treatment Market Trends And Strategies

4. Intestinal Pseudo-Obstruction Treatment Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Intestinal Pseudo-Obstruction Treatment Market Size and Growth

  • 5.1. Global Intestinal Pseudo-Obstruction Treatment Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Intestinal Pseudo-Obstruction Treatment Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Intestinal Pseudo-Obstruction Treatment Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Intestinal Pseudo-Obstruction Treatment Market Segmentation

  • 6.1. Global Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Antibiotics
  • Antidepressants
  • Antidiarrheals
  • 6.2. Global Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Medication
  • Surgery
  • Diet
  • Decompression
  • Other Treatments
  • 6.3. Global Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oral
  • Intravenous
  • Other Route Of Administrations
  • 6.4. Global Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Physical Examination
  • Biopsy
  • Blood Test
  • Gastric Emptying Tests
  • Imaging Tests
  • Other Diagnosis
  • 6.5. Global Intestinal Pseudo-Obstruction Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Clinic
  • Hospitals
  • Other End Users

7. Intestinal Pseudo-Obstruction Treatment Market Regional And Country Analysis

  • 7.1. Global Intestinal Pseudo-Obstruction Treatment Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Intestinal Pseudo-Obstruction Treatment Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Intestinal Pseudo-Obstruction Treatment Market

  • 8.1. Asia-Pacific Intestinal Pseudo-Obstruction Treatment Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Intestinal Pseudo-Obstruction Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Intestinal Pseudo-Obstruction Treatment Market

  • 9.1. China Intestinal Pseudo-Obstruction Treatment Market Overview
  • 9.2. China Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Intestinal Pseudo-Obstruction Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Intestinal Pseudo-Obstruction Treatment Market

  • 10.1. India Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Intestinal Pseudo-Obstruction Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Intestinal Pseudo-Obstruction Treatment Market

  • 11.1. Japan Intestinal Pseudo-Obstruction Treatment Market Overview
  • 11.2. Japan Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Intestinal Pseudo-Obstruction Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Intestinal Pseudo-Obstruction Treatment Market

  • 12.1. Australia Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Intestinal Pseudo-Obstruction Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Intestinal Pseudo-Obstruction Treatment Market

  • 13.1. Indonesia Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Intestinal Pseudo-Obstruction Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Intestinal Pseudo-Obstruction Treatment Market

  • 14.1. South Korea Intestinal Pseudo-Obstruction Treatment Market Overview
  • 14.2. South Korea Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Intestinal Pseudo-Obstruction Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Intestinal Pseudo-Obstruction Treatment Market

  • 15.1. Western Europe Intestinal Pseudo-Obstruction Treatment Market Overview
  • 15.2. Western Europe Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Intestinal Pseudo-Obstruction Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Intestinal Pseudo-Obstruction Treatment Market

  • 16.1. UK Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Intestinal Pseudo-Obstruction Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Intestinal Pseudo-Obstruction Treatment Market

  • 17.1. Germany Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Intestinal Pseudo-Obstruction Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Intestinal Pseudo-Obstruction Treatment Market

  • 18.1. France Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Intestinal Pseudo-Obstruction Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Intestinal Pseudo-Obstruction Treatment Market

  • 19.1. Italy Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Intestinal Pseudo-Obstruction Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Intestinal Pseudo-Obstruction Treatment Market

  • 20.1. Spain Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Intestinal Pseudo-Obstruction Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Intestinal Pseudo-Obstruction Treatment Market

  • 21.1. Eastern Europe Intestinal Pseudo-Obstruction Treatment Market Overview
  • 21.2. Eastern Europe Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Intestinal Pseudo-Obstruction Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Intestinal Pseudo-Obstruction Treatment Market

  • 22.1. Russia Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Intestinal Pseudo-Obstruction Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Intestinal Pseudo-Obstruction Treatment Market

  • 23.1. North America Intestinal Pseudo-Obstruction Treatment Market Overview
  • 23.2. North America Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Intestinal Pseudo-Obstruction Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Intestinal Pseudo-Obstruction Treatment Market

  • 24.1. USA Intestinal Pseudo-Obstruction Treatment Market Overview
  • 24.2. USA Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Intestinal Pseudo-Obstruction Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Intestinal Pseudo-Obstruction Treatment Market

  • 25.1. Canada Intestinal Pseudo-Obstruction Treatment Market Overview
  • 25.2. Canada Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Intestinal Pseudo-Obstruction Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Intestinal Pseudo-Obstruction Treatment Market

  • 26.1. South America Intestinal Pseudo-Obstruction Treatment Market Overview
  • 26.2. South America Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Intestinal Pseudo-Obstruction Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Intestinal Pseudo-Obstruction Treatment Market

  • 27.1. Brazil Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Intestinal Pseudo-Obstruction Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Intestinal Pseudo-Obstruction Treatment Market

  • 28.1. Middle East Intestinal Pseudo-Obstruction Treatment Market Overview
  • 28.2. Middle East Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Intestinal Pseudo-Obstruction Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Intestinal Pseudo-Obstruction Treatment Market

  • 29.1. Africa Intestinal Pseudo-Obstruction Treatment Market Overview
  • 29.2. Africa Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Intestinal Pseudo-Obstruction Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Intestinal Pseudo-Obstruction Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Intestinal Pseudo-Obstruction Treatment Market Competitive Landscape And Company Profiles

  • 30.1. Intestinal Pseudo-Obstruction Treatment Market Competitive Landscape
  • 30.2. Intestinal Pseudo-Obstruction Treatment Market Company Profiles
    • 30.2.1. F. Hoffmann-La Roche AG
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Merck Sharp & Dohme Corp
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Bayer AG
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Sanofi S.A.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. AstraZeneca plc
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Intestinal Pseudo-Obstruction Treatment Market Other Major And Innovative Companies

  • 31.1. GSK plc
  • 31.2. Takeda Pharmaceutical Company Limited
  • 31.3. Amgen PLC
  • 31.4. Boehringer Ingelheim International GmbH
  • 31.5. Teva Pharmaceutical Industries Ltd.
  • 31.6. Astellas Pharma Inc.
  • 31.7. Mylan N.V.
  • 31.8. Biogen Inc.
  • 31.9. Penn Medicine
  • 31.10. Sun Pharmaceutical Industries Ltd.
  • 31.11. Aurobindo Pharma Ltd
  • 31.12. Cipla Inc.
  • 31.13. Dr. Reddy's Laboratories Ltd.
  • 31.14. Allergan plc
  • 31.15. Torrent Pharmaceuticals Limited

32. Global Intestinal Pseudo-Obstruction Treatment Market Competitive Benchmarking

33. Global Intestinal Pseudo-Obstruction Treatment Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Intestinal Pseudo-Obstruction Treatment Market

35. Intestinal Pseudo-Obstruction Treatment Market Future Outlook and Potential Analysis

  • 35.1 Intestinal Pseudo-Obstruction Treatment Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Intestinal Pseudo-Obstruction Treatment Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Intestinal Pseudo-Obstruction Treatment Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer